Master Class

How congenital heart disease affects brain development


 

Congenital heart disease (CHD) is the most common congenital anomaly, with an estimated incidence of 6-12 per 1,000 live births. It is also the congenital anomaly that most often leads to death or significant morbidity. Advances in surgical procedures and operating room care as well as specialized care in the ICU have led to significant improvements in survival over the past 10-20 years – even for the most complex cases of CHD. We now expect the majority of newborns with CHD not only to survive, but to grow up into adulthood.

The focus of clinical research has thus transitioned from survival to issues of long-term morbidity and outcomes, and the more recent literature has clearly shown us that children with CHD are at high risk of learning disabilities and other neurodevelopmental abnormalities. The prevalence of impairment rises with the complexity of CHD, from a prevalence of approximately 20% in mild CHD to as much as 75% in severe CHD. Almost all neonates and infants who undergo palliative surgical procedures have neurodevelopmental impairments.

Quantitative volumetric MRI analysis of the fetal brain: Axial view of 3D fetal cortex and computer based segmentation Courtesy Catherine Limperopoulos, PhD, Children's National

Quantitative volumetric MRI analysis of the fetal brain: Axial view of 3D fetal cortex (green), and computer based segmentation. Red: External cerebrospinal fluid. Dark Blue: White matter. Light Blue: Lateral ventricles. Tan: Subcortical gray matter.

A 2012 American Heart Association scientific statement significantly advanced the attention paid to neurodevelopmental outcomes in children with CHD by proposing evaluation and management strategies specifically for these children (Circulation. 2012 Aug 27;126:1143-72). The statement offers algorithms based partly on levels of risk, but it also emphasizes that levels of risk can change over time, and that continued surveillance is critical even in patients who are initially categorized as low risk.

The neurobehavioral “signature” of CHD includes cognitive defects (usually mild), short attention span, fine and gross motor delays, speech and language delays, visual motor integration, and executive function deficits. Executive function deficits and attention deficits are among the problems that often do not present in children until they reach middle school and beyond, when they are expected to learn more complicated material and handle more complex tasks. Long-term surveillance and care have thus become a major focus at our institution and others throughout the country.

At the same time, evidence has increased in the past 5-10 years that adverse neurodevelopmental outcomes in children with complex CHD may stem from genetic factors as well as compromise to the brain in utero because of altered blood flow, compromise at the time of delivery, and insults during and after corrective or palliative surgery. Surgical strategies and operating room teams have become significantly better at protecting the brain, and new research now is directed toward understanding the neurologic abnormalities that are present in newborns prior to surgical intervention.

Increasingly, researchers are now focused on looking at the in utero origins of brain impairments in children with CHD and trying to understand specific prenatal causes, mechanisms, and potentially modifiable factors. We’re asking what we can do during pregnancy to improve neurodevelopmental outcomes.

Impaired brain growth

The question of how CHD affects blood flow to the fetal brain is an important one. We found some time ago in a study using Doppler ultrasound that 44% of fetuses with CHD had blood flow abnormalities in the middle cerebral artery at some point in the late second or third trimester, suggesting that the blood vessels had dilated to allow more cerebral perfusion. This phenomenon, termed “brain sparing,” is believed to be an autoregulatory mechanism that occurs as a result of diminished oxygen delivery or inadequate blood flow to the brain (Pediatr Cardiol. 2003 Jan;24[5]:436-43).

Subsequent studies have similarly documented abnormal cerebral blood flow in fetuses with various types of congenital heart lesions. What is left to be determined is whether this autoregulatory mechanism is adequate to maintain perfusion in the presence of specific, high-risk CHD.

Fetal echocardiogram at 24 weeks shows hypoplastic left heart syndrome Courtesy Dr. Donofrio

Fetal echocardiogram at 24 weeks shows hypoplastic left heart syndrome. The images shows a small, scarred (bright) left ventricle, normal (red) tricuspid inflow and no mitral inflow.

More recently, researchers have been using more advanced technologies to look not only at blood flow patterns but also at brain growth and development throughout gestation. One study compared brain volume and metabolic factors representative of brain development in 55 fetuses with CHD to 50 normal fetuses using 3-D volumetric MRI and magnetic resonance spectroscopy. It found that brain growth was progressively and significantly slower in the third trimester in fetuses with CHD, leading to decreased brain volume. Brain metabolites relating to neuroaxonal development also fell off during the third trimester.

Abnormalities were more often seen in CHD with obstructed aortic flow, such as hypoplastic left heart syndrome (HLHS) in which the aorta is perfused retrograde through the fetal ductus arteriosus (Circulation. 2010 Jan 4;121:26-33).

Other fetal imaging studies have similarly demonstrated a progressive third-trimester decrease in both cortical gray and white matter and in gyrification (cortical folding) (Cereb Cortex. 2013;23:2932-43), as well as decreased cerebral oxygen delivery and consumption (Circulation. 2015;131:1313-23) in fetuses with severe CHD. It appears that the brain may start out normal in size, but in the third trimester, the accelerated metabolic demands that come with rapid growth and development are not sufficiently met by the fetal cardiovascular circulation in CHD.

In the newborn with CHD, preoperative brain imaging studies have demonstrated structural abnormalities suggesting delayed development (for example, microcephaly and a widened operculum), microstructural abnormalities suggesting abnormal myelination and neuroaxonal development, and lower brain maturity scores (a composite score that combines multiple factors, such as myelination and cortical in-folding, to represent “brain age”).

Moreover, some of the newborn brain imaging studies have correlated brain MRI findings with neonatal neurodevelopmental assessments. For instance, investigators found that full-term newborns with CHD had decreased gray matter brain volume and increased cerebrospinal fluid volume and that these impairments were associated with poor behavioral state regulation and poor visual orienting (J Pediatr. 2014;164:1121-7).

Interestingly, it has been found that the full-term baby with specific complex CHD, including newborns with single ventricle CHD or transposition of the great arteries, is more likely to have a brain maturity score that is equivalent to that of a baby born at 35 weeks’ gestation. This means that, in some infants with CHD, the brain has lagged in growth by about a month, resulting in a pattern of disturbed development and subsequent injury that is similar to that of premature infants.

It also means that infants with CHD and an immature brain are especially vulnerable to brain injury when open-heart surgery is needed. In short, we now appreciate that the brain in patients with CHD is likely more fragile than we previously thought – and that this fragility is prenatal in its origins.

Pages

Recommended Reading

Breastfeeding may reduce moms’ stroke risk
MDedge Neurology
Prenatal methadone maintenance linked to poorer child neurodevelopment
MDedge Neurology
Early neuroimaging essential for Zika-exposed neonates
MDedge Neurology
Teratogenicity may not be a yes or no question
MDedge Neurology
MDedge Daily News: Why most heart failure may be preventable
MDedge Neurology
Pregnant women in clinical trials: FDA questions how to include them
MDedge Neurology
MDedge Daily News: Fewer smokes mean fewer strokes
MDedge Neurology
MDedge Daily News: How to handle opioid constipation
MDedge Neurology
Pregnancy may be ideal time to consider switching MS drugs
MDedge Neurology
NIH launches HEAL Initiative to combat opioid crisis
MDedge Neurology